Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PAL who wrote (4361)	5/21/1998 5:35:00 PM
From: Bhag Karamchandani	Read Replies (3) of 6136

" Unfortunately, scientists are from a good PR person." Just what did you mean?? If ML model to valuation of AGPH were applied to all biotechs, 60-70 % of them (those with no revenue stream and no valuation for potential drugs in pipeline) would have stock prices of zero. There would be nothing wrong with this approach if ML consistently applied it to valuation of all biotechs and not merely AGPH. On the other hand, as I have noted before, AGPH has spent hundreds of millions of dollars on R & D over seven years (?) and has yet to bring an in-house designed drug to market. Let us hope AG 3340 fares better than Thymatiq. Hope someone can explain why. It may be comforting to AGPH longs. Cheers.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next